RemeGen Co., Ltd. REGMF
9.96 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
10.73 Day range 10.93
9.54 52-week range 12.85
- YTD
- +1.53%
- 1 year
- -9.45%
News
reuters.com AbbVie, RemeGen partner on experimental solid tumor treatment AbbVie said on Monday it would partner with RemeGen to develop an experimental treatment for solid tumors in a deal worth up to $4.95 billion, including milestones.
defenseworld.net Short Interest in RemeGen Co., Ltd. (OTCMKTS:REGMF) Drops By 45.0% RemeGen Co., Ltd. (OTCMKTS:REGMF - Get Free Report) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totaling 194,690 shares, a…
prnewswire.com RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an…
prnewswire.com RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA YANTAI, China , Aug. 8, 2025 /PRNewswire/ -- On August 8 th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical…
businesswire.com PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset & $175M Private Placement.
prnewswire.com RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis YANTAI, China , June 17, 2025 /PRNewswire/ -- On June 16, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand name: 泰爱®) has received…
prnewswire.com RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China YANTAI, China , May 27, 2025 /PRNewswire/ -- On May 27, RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical…
prnewswire.com Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis YANTAI, China , April 8, 2025 /PRNewswire/ -- On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym:…